Donor characteristics
| . | Healthy donors . | Multiple myeloma . | Non-Hodgkin lymphoma . |
|---|---|---|---|
| No. of patients | 8 | 10 | 10 |
| Median age in years (range) | 38 (20-49) | 59 (52-68) | 51 (21-64) |
| Sex (male/female) | 4/4 | 5/5 | 6/4 |
| Mobilization regimen | |||
| G-CSF (8 μg/kg/day subcutaneously)† | 8 | 0 | 0 |
| G-CSF (30 μg/kg/day subcutaneously)* | 0 | 1 | 0 |
| CY (2 g/m2intravenously) + G-CSF (10 μg/kg/day subcutaneously)† | — | 3 | 3 |
| CY (2-4 g/m2intravenously) + G-CSF (30 μg/kg/day subcutaneously)* | — | 6 | 7 |
| Disease status at mobilization, no. (%) | |||
| Complete hematologic remission | — | 0 (0%) | 7 (70%) |
| Partial remission | — | 2 (20%) | 3 (30%) |
| Plateau | — | 5 (50%) | 0 (0%) |
| Progressive disease | — | 3 (30%) | 0 (0%) |
| Prior chemotherapy, no. (%)‡ | |||
| Untreated | — | 0 (0%) | 0 (0%) |
| 1-2 regimens of therapy | — | 9 (90%) | 10 (100%) |
| Prior radiotherapy, no. (%) | — | 3 (30%) | 2 (20%) |
| . | Healthy donors . | Multiple myeloma . | Non-Hodgkin lymphoma . |
|---|---|---|---|
| No. of patients | 8 | 10 | 10 |
| Median age in years (range) | 38 (20-49) | 59 (52-68) | 51 (21-64) |
| Sex (male/female) | 4/4 | 5/5 | 6/4 |
| Mobilization regimen | |||
| G-CSF (8 μg/kg/day subcutaneously)† | 8 | 0 | 0 |
| G-CSF (30 μg/kg/day subcutaneously)* | 0 | 1 | 0 |
| CY (2 g/m2intravenously) + G-CSF (10 μg/kg/day subcutaneously)† | — | 3 | 3 |
| CY (2-4 g/m2intravenously) + G-CSF (30 μg/kg/day subcutaneously)* | — | 6 | 7 |
| Disease status at mobilization, no. (%) | |||
| Complete hematologic remission | — | 0 (0%) | 7 (70%) |
| Partial remission | — | 2 (20%) | 3 (30%) |
| Plateau | — | 5 (50%) | 0 (0%) |
| Progressive disease | — | 3 (30%) | 0 (0%) |
| Prior chemotherapy, no. (%)‡ | |||
| Untreated | — | 0 (0%) | 0 (0%) |
| 1-2 regimens of therapy | — | 9 (90%) | 10 (100%) |
| Prior radiotherapy, no. (%) | — | 3 (30%) | 2 (20%) |
CY indicates cyclophosphamide (Endoxan-Astra, Parramatta, NSW, Australia); G-CSF, granulocyte-colony stimulating factor (Filgrastim; Amgen, Thousand Oaks, CA); —, not applicable.
Filled symbols as indicated in Figures 1 and 2.
Open symbols as indicated in Figures 1 and 2.
No significant difference was noted in the intensity of chemotherapeutic regimens between the MM and NHL patient groups. Four NHL patients were treated with the anti-CD20 monoclonal antibody Mabthera (Roche Pharmaceuticals, Dee Why, NSW, Australia) concurrently with chemotherapy.